Cannabis Report
High Times
Home > Boards > US Listed > Biotechs >

Soleno Therapeutics, Inc. (SLNO)

SLNO RSS Feed 		Add SLNO Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 6/22/2018 5:12:57 PM - Followers: 21 - Board type: Free - Posts Today: 0

Soleno (SLNO) is a new formed company  through the merger between Capnia and the private Essentials (merger completed in march 2017) . SLNO has a potential BLOCKBUSTER in Phase 3 for the treatment of Prader Willi Syndrome a Rare Disease for which there is no approved treatments  . This unknown low float stock which has a terrible low valuation of $16 million could be the next SRPT the stock should be valued above $100 million right now for their Phase 3 Program and in the Billions if the outcome of the Phase 3 trial is positive which expected by next year .GL

Soleno therapeutics (SLNO)

Market Cap $16 Million
Cash: $8 Million
Price $0.35

Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)


$2.3 BILLION Market Potential for the Prader Willi Syndrome no approved treatments for this Indication


Maxim Group set a $5.00 target price on Capnia, Inc. (NASDAQ:SLNO) in a research note issued to investors on Wednesday, July 5th. The firm currently has a buy rating on the stock.
https://www.thecerbatgem.com/2017/08/04/maxim-group-analysts-give-capnia-inc-slno-a-5-00-price-target-updated-updated-updated.html



Initiating Coverage June 26, 2017
http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

Market Opportunity for PWS is Substantial.

While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.


VERY Strong Insiders & Institutional ownership :

Vivo Ventures LLC     16 012 808   
Forward Ventures Services LLC     7 251 728   
Technology Partners     7 050 691   
Aspire Capital Partners LLC     2 791 666   
Ernest Mario, PhD     1 844 328   
Oppenheim Asset Management Services SARL     574 853   
Medical Strategy GmbH     503 305   
Palo Alto Investors LLC     423 738   
Sabby Capital LLC     248 067   
The Bollard Group LLC  192 217   



Cannabis Report
High Times
SLNO
Current Price
Volume:
Bid Ask Day's Range
SLNO Detailed Quote
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SLNO News: Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease 09/19/2018 08:00:00 AM
SLNO News: Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinol... 09/17/2018 08:00:00 AM
SLNO News: Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patien... 09/06/2018 08:00:00 AM
SLNO News: Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi S... 09/04/2018 08:00:00 AM
SLNO News: Quarterly Report (10-q) 08/14/2018 04:35:17 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#153   * * $SLNO Video Chart 06-22-18 * * ClayTrader 06/22/18 05:12:57 PM
#152   Yup nice General Grievous 06/22/18 04:06:19 PM
#151   Nice close! Next week SLNO heads to $14. crudeoil24 06/22/18 04:05:25 PM
#150   Last 3 months up 51% crudeoil24 06/22/18 10:16:57 AM
#149   Super low floater > 9.6M trading float; it crudeoil24 06/22/18 10:14:39 AM
#148   U think it’ll fill the gap more than General Grievous 06/22/18 10:10:35 AM
#147   K sounds good General Grievous 06/22/18 10:09:44 AM
#146   Average volume is 51K. I say intra-day consolidation, crudeoil24 06/22/18 10:09:23 AM
#145   Yeah it hit its previous resistance on chart General Grievous 06/22/18 10:02:04 AM
#144   Day traders all over this now. Ton of crudeoil24 06/22/18 10:01:21 AM
#143   Crazy target eh General Grievous 06/22/18 09:49:30 AM
#142   Soleno Therapeutics Price Target Announced at $14.00/Share by crudeoil24 06/22/18 08:52:13 AM
#141   * * $SLNO Video Chart 12-08-17 * * ClayTrader 12/08/17 05:21:05 PM
#140   Oh my! A low of $1.83 ($0.366 pre-split) 236T568 10/20/17 12:18:15 PM
#139   SLNO 1-5 REVERSE SPLIT! 236T568 10/05/17 01:05:22 PM
#138   * * $SLNO Video Chart 09-15-17 * * ClayTrader 09/15/17 04:52:07 PM
#137   $1 coming closer BioSpecialist 09/15/17 11:42:53 AM
#136   Great News out , if this Drug also BioSpecialist 09/15/17 09:56:39 AM
#135   Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics BioSpecialist 09/14/17 08:50:06 AM
#134   this stock will explode to $1++ anytime now ... BioSpecialist 09/13/17 03:54:07 PM
#133   Great News out stock exploding in pre market .. BioSpecialist 09/13/17 09:25:49 AM
#132  Restored SLNO CFO abruptly RESIGNS! 236T568 09/06/17 01:55:33 AM
#131   Once we break the MA (200) at 0.69 BioSpecialist 09/01/17 10:04:22 AM
#130   and back up again ... BioSpecialist 08/31/17 01:25:32 PM
#129   consolidation today created great buying opp BioSpecialist 08/30/17 01:03:20 PM
#128   looks like another green day ,,love it BioSpecialist 08/29/17 09:42:35 AM
#127   $1+ coming guys BioSpecialist 08/28/17 10:02:37 AM
#126   Nice slap getting attention Awl416 08/25/17 03:23:46 PM
#125   new highs coming soon BioSpecialist 08/25/17 02:39:31 PM
#124   this hot stock just formed a few months BioSpecialist 08/25/17 10:11:59 AM
#123   this could be the next SRPT here BioSpecialist 08/23/17 02:00:23 PM
#122   SLNO(Market-Cap $19 M) Potential Blockbuster Drug in Phase BioSpecialist 08/16/17 12:39:35 PM
#121   yep and i have a feeling this might W.S.S 07/09/17 04:41:43 PM
#120   Once it break .75 we are going to Rodney213 07/09/17 09:58:38 AM
#119   Target: 4.50$+ Next Week thaier 07/07/17 02:31:40 PM
#118   Wellll, my nose hairs were twitching awright, Wildbilly 04/22/17 06:02:04 AM
#117   CAPN $.62: Large insider buy, insider share grants, Wildbilly 04/16/17 07:50:02 AM
#116   You mean after today...Hopefully tomorrow? Instrumentalist 12/27/16 11:43:49 PM
#115   Big bounce play coming today Moto260 12/27/16 09:33:11 AM
#114   Took a starter here today. Chart looks like rivervalley 08/18/16 01:21:14 PM
#113   WTF BILL!!! DrShocker 07/31/16 04:23:20 PM
#112   volume picking up on news .. WarChest 06/08/16 10:15:37 AM
#111   Audio from 5th Annual Marcum MicroCap Conference (June tencoin 06/02/16 08:06:01 AM
#110   Pharmacies where to buy SERENZ tencoin 06/02/16 05:18:31 AM
#109   Video about SERENZ and Pharmacies online: tencoin 06/02/16 12:21:48 AM
#108   Started selling SERENZ in British pharmacies. tencoin 04/27/16 08:14:44 AM
#106   I developed an artificial lung that take in bill897 09/25/15 07:54:38 PM
#105   I developed an artificial lung that take in bill897 09/25/15 07:48:47 PM
#104   Best stock to short whenever it gaps up Stock8049 09/24/15 10:56:52 AM
#103   NICE!! 1/2 OF FLOAT ABOUT TO TRADE= http://www.finviz.com/quote.ashx?t=CA [SMART MONEY] 09/24/15 10:16:42 AM
PostSubject
© 2018 InvestorsHub.com, Inc.